Background and Objectives: Anastomotic leakage (AL) is a major complication following sphincter-preserving surgeries for left-sided colorectal cancer. In this study, we aimed to evaluate the association between circular stapler diameter and the risk of AL. As a secondary objective, we investigated whether preoperative serum protein levels were associated with leakage development. Materials and Methods: We conducted a retrospective case–control study including 99 patients who underwent elective colorectal surgery with stapled anastomosis for left-sided colorectal cancer between January 2020 and May 2024. A total of 99 patients were included (60.6% male), with a mean age of 66.1 ± 10.7 years. The patients were categorized into small (≤29 mm) and large (≥30 mm) stapler groups. Demographic, clinical, and laboratory variables were collected. Anastomotic leakage was defined as an International Study Group of Rectal Cancer (ISREC) Grade B or C leak requiring intervention. Univariate analyses and multivariate logistic regression analyses were performed, and results were reported as odds ratios (ORs) with 95% confidence intervals (CIs). A STROBE-compliant flow diagram was prepared. Results: Anastomotic leakage occurred in 10 patients (10.1%), and leakage rates were not significantly different between stapler-size groups (≤29 mm: 10.9% vs. ≥30 mm: 7.5%, p = 0.365). In multivariate analysis, stapler size was not independently associated with leakage (OR 1.68, 95% CI 0.40–6.97, p = 0.480). Lower preoperative serum protein levels were identified as the only independent predictor of leakage (OR 0.28, 95% CI 0.10–0.74, p = 0.011). Postoperative hospital stay was significantly longer for patients with leakage (median 17 vs. 7 days, p < 0.001). Conclusions: We found no significant associations between circular stapler diameter and anastomotic leakage in left-sided colorectal cancer surgery. Conversely, low serum protein levels were independently associated with increased leakage risk, highlighting the importance of preoperative nutritional assessment. Given the retrospective design, small number of leakage cases, and unmeasured confounders, these findings should be interpreted with caution. Further multicenter, prospective studies should be conducted to clarify the influence of stapler size and patient-related factors on anastomotic outcomes.

Introduction Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by persistent abdominal pain and variable bowel patterns, impacting individuals' quality of life. Despite its functional nature, recent research has indicated the role of inflammatory processes in IBS development. This study aims to investigate the potential diagnostic value of routine blood parameters and their relationship with IBS. Methods In this retrospective analysis, patients diagnosed with IBS based on the ROME IV criteria were identified from the outpatient clinic of Hitit University Erol Olçok Teaching and Research Hospital between January 1, 2023, and May 1, 2023. Exclusion criteria encompassed specific medical conditions, psychiatric disorders, and organic bowel pathologies. A cohort of 100 IBS patients and 100 healthy controls were included for comparison. Comprehensive blood data, including neutrophil count, lymphocyte count, hemoglobin level, red cell distribution width (RDW), mean corpuscular volume (MCV), mean platelet volume (MPV), and platelet count, were collected. Statistical analyses were conducted using SPSS for Windows version 26.0 (IBM Corp., Armonk, NY). Descriptive statistics, Pearson's or Spearman's correlation coefficients, Mann-Whitney U test, and Chi-square test were used to analyze data. Results The study cohort consisted of 70 men (35%) and 130 women (65%). The average age was 51.65 ± 14.64 years (52 years). The mean neutrophil count was 4.6 ± 1.5 (4.29) in the control group and 4.7 ± 2.03 (4.12) in the IBS group. The mean lymphocyte count was 2.3 ± 0.86 (2.21) in the control group and 2.3 ± 0.82 (2.23) in the IBS group, indicating no statistically significant difference (p = 0.732). The mean RDW was measured as 13.62 ± 1.07 (13.4) in the control group and 13.68 ± 1.18 (13.55) in the IBS group, again demonstrating no significant difference (p = 0.915). Mean MCV and MPV values showed no substantial variation between the control and IBS groups (p = 0.649 and p = 0.406, respectively). Conclusion While this study did not yield statistically robust outcomes, it underscores the potential of utilizing neutrophil-to-lymphocyte ratio (NLR), RDW, and MPV as adjunctive diagnostic markers for IBS. These routine and cost-effective parameters could enhance the diagnostic process, especially in cases with suspected IBS. Continued research is essential to unravel their complete diagnostic potential and clinical applicability.

Background and Objectives: Anastomotic leakage (AL) is a major complication of colorectal surgery (CRS), increasing morbidity, mortality, and healthcare costs. While several AL risk factors have been identified, the role of aortic calcification (AC) remains unclear. As a marker of systemic atherosclerosis, AC may impair tissue perfusion and anastomotic healing. Additionally, tumor factors (TNM stage, histology, and localization) and patient comorbidities (hypertension, cardiovascular disease, and neoadjuvant therapy) may contribute to AL risk. This study evaluates the association between preoperative AC and AL incidence while considering additional risk factors. Materials and Methods: This retrospective cohort study included 151 patients undergoing CRS from January 2020 to October 2023. Preoperative CT scans classified AC into Stage 0 (none), Stage 1 (50%) of the aortic circumference. Data on demographics, tumor characteristics, neoadjuvant therapy, and comorbidities were collected. AL risk factors were analyzed using univariate and multivariate logistic regression. Results: AL occurred in 5.96% (9/151) of patients. AL incidence was significantly higher in patients with >50% AC (44.47% vs. 11.27%, p = 0.012). Multivariate analysis confirmed AC as an independent AL predictor (OR = 10.38, 95% CI: 1.243–92.118, p = 0.032). Rectal tumor localization (p = 0.038), hypertension (p = 0.027), cardiovascular disease (p = 0.014), and neoadjuvant therapy (p = 0.045) were also associated with increased AL risk. Conclusions: Severe AC is an independent predictor of AL in CRS. Additionally, rectal tumors, hypertension, cardiovascular disease, and neoadjuvant therapy contribute to AL risk. Preoperative vascular assessments and comprehensive risk stratification models may help identify high-risk patients and guide perioperative management strategies to reduce AL incidence.

Background/Aim: Lymphovascular and perineural invasion (LVI and PNI, respectively) are associated with poor prognosis in various cancers. We sought to identify clinical variables associated with LVI and PNI in colorectal cancer (CRC) and their effects on survival. Methods: Our study design is consistent with a retrospective cohort study. Data from 237 patients with documented LVI or PNI who underwent surgery for colorectal cancer between 2017 and 2021 were retrospectively reviewed. Demographic characteristics, surgery and pathology reports, disease-free and overall survival (DFS and OS, respectively) of the patients were examined. Results: When the DFS duration of the patients were evaluated, The mean DFS of the LVI-negative group was 27.4 (15.09) months, and the mean of the LVI-positive patients was 20.45 (13) months. DFS was longer in the LVI-negative group (P<0.001). DFS was 52.26 (1.89) months in PNI-negative patients and 34.29 (2.71) months in PNI-positive patients. DFS expectation of PNI-positive patients was approximately 18 months less than that of negative patients (P<0.001). When the patients were evaluated in terms of OS duration, no significant difference was observed in LVI-negative and -positive patient groups, while the estimated OS duration was 52.29 (1.84) months in PNI-negative patients, and 40.10 (2.49) months in PNI-positive patients. OS was 12 months shorter in PNI-negative patients (P<0.001). Conclusion: The use of PNI and LVI together was found to have a significant impact on the survival rates of patients with colorectal cancer. Documenting LVI and PNI status in biopsy specimens can aid in the management, prognosis, and decision-making for treating colorectal tumors. function ready(callback){ // in case the document is already rendered if (document.readyState!='loading') callback(); // modern browsers else if (document.addEventListener) document.addEventListener('DOMContentLoaded', callback); // IE <= 8 else document.attachEvent('onreadystatechange', function(){ if (document.readyState=='complete') callback(); }); } ready(function(){ var abstract = document.getElementById("abstract"); //declare your possible strings in vars let st = innerHTML; st = st.replace(//g,""); st = st.replace(/<\/p>/g,""); st = st.replace(//g,""); st = st.replace(/<\/strong>/g,""); st = st.replace(/ /g,""); let title = "Background/Aim:"; if(st.includes(title)){ st = st.replace(title, ""+title+" "); } else{ title = "Aim:"; st = st.replace(title, ""+title+""); } let titles = ["Methods:", "Conclusion:", "Results:"]; titles.forEach((title, ndx) => { //console.log(title); st = st.replace(title, " "+title+""); }); //console.log(st); innerHTML = ''+st+''; }); Downloads Download data is not yet available. References Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7-33. DOI: https://doi.org/10.3322/caac.21708 Guyot F, Faivre J, Manfredi S, Meny B, Bonithon-Kopp C, Bouvier A. Time trends in the treatment and survival of recurrences from colorectal cancer. Ann Oncol. 2005;16(5):756-61. DOI: https://doi.org/10.1093/annonc/mdi151 Edge, Stephen B, Carolyn C. Compton. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471-74. DOI: https://doi.org/10.1245/s10434-010-0985-4 McLeod HL, Murray GI. Tumour markers of prognosis in colorectal cancer. Br J Cancer. 1999;79(2):191-203. DOI: https://doi.org/10.1038/sj.bjc.6690033 Schneider NI, Langner C. Prognostic stratification of colorectal cancer patients: current perspectives. Cancer Manag Res. 2014 Jul 2;6:291-300. DOI: https://doi.org/10.2147/CMAR.S38827 Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 Mar 2;19(3):329-59. Argilés G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Oct;31(10):1291-305. DOI: https://doi.org/10.1016/j.annonc.2020.06.022 Benson AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22:3408–19. DOI: https://doi.org/10.1200/JCO.2004.05.063 Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandalà M, Cervantes A, et al. Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;24(6):64–72. DOI: https://doi.org/10.1093/annonc/mdt354 Benson AB 3rd, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, et al. Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(3):370–98. DOI: https://doi.org/10.6004/jnccn.2017.0036 Weiss JM, Schumacher J, Allen GO, Neuman H, Lange EO, Loconte NK, et al. Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data. Ann Surg Oncol. 2014 Jun;21(6):1781-91. DOI: https://doi.org/10.1245/s10434-014-3631-8 Booth CM, Nanji S, Wei X, Peng Y, Biagi JJ, Hanna TP, Krzyzanowska MK, Mackillop WJ. Adjuvant Chemotherapy for Stage II Colon Cancer: Practice Patterns and Effectiveness in the General Population. Clin Oncol (R Coll Radiol). 2017 Jan;29(1):e29-e38. doi: 10.1016/j.clon.2016.09.001. Epub 2016 Sep 20. PMID: 27663601. DOI: https://doi.org/10.1016/j.clon.2016.09.001 Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000 Jul;124(7):979-94. DOI: https://doi.org/10.5858/2000-124-0979-PFICC Liebig C, Ayala G, Wilks J, Verstovsek G, Liu H, Agarwal N, et al. Perineural invasion is an independent predictor of outcome in colorectal cancer. J Clin Oncol. 2009; 27(31): 5131 DOI: https://doi.org/10.1200/JCO.2009.22.4949 Harris EI, Lewin DN, Wang HL, Lauwers GY, Srivastava A, Shyr Y, et al. Lymphovascular invasion in colorectal cancer: an interobserver variability study. Am J Surg Pathol.2008;32:1816–21. DOI: https://doi.org/10.1097/PAS.0b013e3181816083 Yuan H, Dong Q, Zheng B, Hu X, Xu JB, Tu S. Lymphovascular invasion is a high risk factor for stage I/II colorectal cancer: a systematic review and meta-analysis. Oncotarget 2017;8:46565–79. DOI: https://doi.org/10.18632/oncotarget.15425 Lim SB, Yu CS, Jang SJ, Kim TW, Kim JH, Kim JC. Prognostic significance of lymphovascular invasion in sporadic colorectal cancer. Dis Colon Rectum.2010;53:377–84. DOI: https://doi.org/10.1007/DCR.0b013e3181cf8ae5 Beard CJ, Chen MH, Cote K. Loffredo M, Renshaw AA, Hurwitz M, et al. Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer. Int J Radiat Oncol Biol Phys. 2004;58:19–24. DOI: https://doi.org/10.1016/S0360-3016(03)01433-0 Harnden P, Shelley MD, Clements H, Coles B, Tyndale‐Biscoe RS, Naylor B, et al. The prognostic significance of perineural invasion in prostatic cancer biopsies: a systematic review. Cancer-Am Cancer Soc. 2007;109:13–24. DOI: https://doi.org/10.1002/cncr.22388 Mendenhall WM, Amdur RJ, Hinerman RW, Werning JW, Malyapa RS, Villaret, et al. Skin cancer of the head and neck with perineural invasion. Am J Clin Oncol. 2007;30:93–96. DOI: https://doi.org/10.1097/01.coc.0000251224.16075.60 Peng J, Lu JJ, Zhu J, Xu Y, Lu H, Lian P, Cai G, Cai S. Prediction of treatment outcome by CD44v6 after total mesorectal excision in locally advanced rectal cancer. Cancer J. 2008 Jan-Feb;14(1):54-61. doi: 10.1097/PPO.0b013e3181629a67. PMID: 18303484 DOI: https://doi.org/10.1097/PPO.0b013e3181629a67 Matsushima T, Mori M, Kido A, Adachi Y, Sugimachi K. Preoperative estimation of neural invasion in rectal carcinoma. Oncol Rep. 1998; 5(1):73-9. DOI: https://doi.org/10.3892/or.5.1.73 Knijn N, Mogk SC, Teerenstra S, Simmer F, Nagtegaal ID. Perineural Invasion is a Strong Prognostic Factor in Colorectal Cancer: A Systematic Review. Am J Surg Pathol. 2016 Jan;40(1):103-12. DOI: https://doi.org/10.1097/PAS.0000000000000518 Sun Q, Liu T, Liu P, Luo J, Zhang N, et al. Perineural and lymphovascular invasion predicts for poor prognosis in locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery. J Cancer. 2019 May 21;10(10):2243-9. DOI: https://doi.org/10.7150/jca.31473 Hoda SA, Hoda RS, Merlin S, Shamonki J, Rivera M. Issues relating to lymphovascular invasion in breast carcinoma. Adv Anat Pathol. 2006;13:308–15. DOI: https://doi.org/10.1097/01.pap.0000213048.69564.26 Lim TY, Pavlidis P, Gulati S, Pirani T, Samaan M, Chung-Faye G, et al. Vedolizumab in Inflammatory Bowel Disease Associated with Autoimmune Liver Disease Pre- and Postliver Transplantation: A Case Series. Inflamm Bowel Dis. 2016;22:39–40. DOI: https://doi.org/10.1097/MIB.0000000000000906 Huh JW, Lee JH, Kim HR, Kim YJ. Prognostic significance of lymphovascular or perineural invasion in patients with locally advanced colorectal cancer. Am J Surg. 2013;206:758–763 DOI: https://doi.org/10.1016/j.amjsurg.2013.02.010 Zhong JW, Yang SX, Chen RP, Zhou YH, Ye MS, Miao L, et al. Prognostic Value of Lymphovascular Invasion in Patients with Stage III Colorectal Cancer: A Retrospective Study. Med Sci Monit. 2019;25:6043–50. DOI: https://doi.org/10.12659/MSM.918133 Yüksel C, Çulcu S, Gojayev A, Demirci S, Ünal A. E. Prognostic Value of Lymphovascular and Perineural Invasion in Colon Cancer. Acta Oncologica Turcica, 2021;54(2):166-74. DOI: https://doi.org/10.5505/aot.2021.23540 Sibio S, Di Giorgio A, D'Ugo S, Palmieri G, Cinelli L, Formica V, et al. Histotype influences emergency presentation and prognosis in colon cancer surgery. Langenbecks Arch Surg. 2019 Nov;404(7):841-51. DOI: https://doi.org/10.1007/s00423-019-01826-6 Nakamura Y, Hokuto D, Koyama F, Matsuo Y, Nomi T, Yoshikawa T, et al. The Prognosis and Recurrence Pattern of Right- and Left-Sided Colon Cancer in Stage II, Stage III, and Liver Metastasis After Curative Resection. Ann Coloproctol. 2021 Oct;37(5):326-36. DOI: https://doi.org/10.3393/ac.2020.09.14 Osterman E, Mezheyeuski A, Sjöblom T, Glimelius B. Beyond the NCCN Risk Factors in Colon Cancer: An Evaluation in a Swedish Population-Based Cohort. Ann Surg Oncol. 2020 Apr;27(4):1036-45. DOI: https://doi.org/10.1245/s10434-019-08148-3 Zhang C, Yin S, Tan Y, Huang J, Wang P, Hou W, et al. Patient Selection for Adjuvant Chemotherapy in High-Risk Stage II Colon Cancer: A Systematic Review and Meta-Analysis. Am J Clin Oncol. 2020 Apr;43(4):279-87. DOI: https://doi.org/10.1097/COC.0000000000000663 <!-- .main_entry --> Downloads PDF 148 273 Published 2023-02-03 Issue Vol. 7 No. 2 (2023): 138-143 Section Research Article How to Cite 1. Alkurt EG, Kartal B, Tutan MB, Lale A, Aygen E. Prognostic value of lymphovascular and perineural invasion in colorectal cancer: Lymphovascular and perineural invasion in colorectal cancer. J Surg Med [Internet]. 2023 Feb. 3 [cited 2023 Dec. 5];7(2):138-43. Available from: https://jsurgmed.com/article/view/7561 More Citation Formats ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver Download Citation Endnote/Zotero/Mendeley (RIS) BibTeX License Copyright (c) 2023 Ertuğrul Gazi Alkurt, Bahadır Kartal, Mehmet Berksun Tutan; Azmi Lale; Erhan Aygen This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. Citations <!-- AddThis Button BEGIN --> <!-- AddThis Button END --> #7561 <!-- .entry_details -->